Join the Upadacitinib group to help and get support from people like you.
Upadacitinib News
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)
NORTH CHICAGO, Ill., April 29, 2025 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib), 15 mg, once daily, for the t...
Upadacitinib Improves Ulcerative Colitis Outcomes at 12 Months
MONDAY, Dec. 23, 2024 – For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes at 12 months compared with tofacitinib, according to a study...
Long-Term Upadacitinib Use Feasible for Adolescents With Atopic Dermatitis
FRIDAY, Oct. 25, 2024 – Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib is safe and effective through 76 weeks, according to a study published...
U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn's Disease in Adults
NORTH CHICAGO, Ill., May 18, 2023 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of adults w...
Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic Axial Spondyloarthritis
Rinvoq is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA) Rinvoq is the first and only JAK inhibitor approved for...
Rinvoq (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Spondylitis
Across the two pivotal trials, Rinvoq delivered rapid and meaningful disease control with nearly half of ankylosing spondylitis (AS) patients achieving ASAS40 (51% and 44.5% with Rinvoq versus 26% ...
Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., March 16, 2022 /PRNewswire/ – AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib) for the treatment of ...
Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis
NORTH CHICAGO, Ill., Dec. 14, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved Rinvoq® (upadacitinib; 15 mg, once daily) for the t...
FDA Medwatch Alert: FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors That Treat Certain Chronic Inflammatory Conditions
This information is an update to the FDA Drug Safety Communication issued on February 4, 2021. FDA also previously communicated about the safety clinical trial with Xeljanz, Xeljanz XR (tofacitinib)...
FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rheumatoid Arthritis
NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ – AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has...
Further information
Related condition support groups
Crohn's Disease, Ankylosing Spondylitis, Contact Dermatitis, Atopic Dermatitis, Non-Radiographic Axial Spondyloarthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis